Department of Pediatrics, Shenzhen Samii International Medical Center, Shenzhen, Shenzhen Province, China.
Department of Clinical Lab, Weinan Maternal and Child Health Hospital, Shaanxi, Weinan Province, China.
Medicine (Baltimore). 2021 Oct 22;100(42):e27585. doi: 10.1097/MD.0000000000027585.
Mycoplasma pneumoniae (MP) is a common infectious respiratory disease in pediatrics, and macrolide antibiotics are the optimal treatment option. In recent years, there is a significant increase in the resistance of this pathogen to macrolide antibiotics, which makes the clinical treatment of this disease increasingly complex. Shenfu injection (SFI), a herbal extract injection, has advantages of improving immune function, reducing inflammatory reaction, improving curative effect and shortening the course of disease in the treatment of pediatric MP. However, there is a lack of rigorous clinical studies to evaluate the effects of SFI on inflammatory factors and immune function in children with MP.
This study is a prospective, randomized, double-blind, placebo-controlled clinical trial protocol. The objective of this study is to evaluate the effect of SFI on inflammatory factors and immune function in children with MP. Patients meeting the inclusion criteria were randomized in a ratio of 1:1 to either the treatment group (azithromycin + 100 mL 5% glucose injection + 50 mL SFI) or the control group (azithromycin + 150 mL 5% glucose injection). Patients in both groups received the standard treatment for 7 days. The levels of inflammatory factor indexes (C-reactive protein, interleukin-6, interleukin-10, tumor necrosis factor-α) and immune function indexes (immunoglobulin G, immunoglobulin A, immunoglobulin M) in both groups were measured at the beginning of treatment, on the 3rd day of treatment and at the end of treatment. Besides, the time of improvement in clinical symptoms (duration of cough, time of disappearance of lung rales, time of fever reduction, and time of disappearance of lung X-ray infiltrative shadow) and adverse effects in both groups were recorded. Finally, the data were statistically analyzed by SPSS 20.0 software.
In this study, an evaluation was conducted on the effects of SFI on inflammatory factors and immune function in pediatric MP. The results of this experiment will provide a clinical basis for the adjuvant treatment of pediatric MP with SFI.
OSF Registration number.
肺炎支原体(MP)是儿科常见的传染性呼吸道疾病,大环内酯类抗生素是其最佳治疗选择。近年来,该病原体对大环内酯类抗生素的耐药性显著增加,使得该病的临床治疗日益复杂。参附注射液(SFI)是一种中药提取物注射液,在治疗小儿 MP 时具有提高免疫功能、减轻炎症反应、提高疗效、缩短病程等优点。但缺乏严格的临床研究来评估 SFI 对儿童 MP 炎症因子和免疫功能的影响。
本研究是一项前瞻性、随机、双盲、安慰剂对照的临床研究方案。本研究的目的是评估 SFI 对小儿 MP 炎症因子和免疫功能的影响。符合纳入标准的患者按照 1:1 的比例随机分为治疗组(阿奇霉素+100mL5%葡萄糖注射液+50mLSFI)和对照组(阿奇霉素+150mL5%葡萄糖注射液)。两组患者均接受标准治疗 7 天。分别于治疗开始时、治疗第 3 天和治疗结束时检测两组患者的炎症因子指标(C 反应蛋白、白细胞介素-6、白细胞介素-10、肿瘤坏死因子-α)和免疫功能指标(免疫球蛋白 G、免疫球蛋白 A、免疫球蛋白 M)水平。同时记录两组患者临床症状改善时间(咳嗽缓解时间、肺部啰音消失时间、退热时间、肺部 X 线浸润影消失时间)和不良反应发生情况。最后采用 SPSS20.0 软件进行统计学分析。
本研究对 SFI 治疗小儿 MP 后对炎症因子和免疫功能的影响进行了评价,该实验结果将为 SFI 辅助治疗小儿 MP 提供临床依据。
OSF 注册号。